Morphine‐6‐glucuronide concentrations and opioid‐related side effects: a survey in cancer patients

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Pain

• Publication date

  1995-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0304-3959(94)00148-8PMID 7644248
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of renal function on the elimination of morphine and morphine glucuronides

  2004cited by this paper
• Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration

  2004cited by this paper
• Kinetics of morphine in patients with renal failure

  2004cited by this paper
• Concentrations of morphine, morphine‐6‐glucuronide and morphine‐3‐glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine‐resistant pain

  1994cited by this paper
• The metabolite morphine‐6‐glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function

  1992cited by this paper
• Chronic nausea and morphine-6-glucuronide.

  1991cited by this paper
• Chronic morphine therapy for cancer pain

  1991cited by this paper
• Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine‐6‐glucuronide

  1990cited by this paper
• Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine.

  1990cited by this paper
• Oral morphine in cancer pain: influences on morphine and metabolite concentration

  1990cited by this paper
• Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites.

  1989cited by this paper
• Long lasting respiratory depression induced by morphine-6-glucuronide?

  1989cited by this paper
• M6G and its analgesic action in chronic use.

  1989cited by this paper
• Analgesic activity of morphine-6-glucuronide.

  1988cited by this paper
• Effects of Renal Insufficiency on the Pharmacokinetics and Pharmacodynamics of Opioid Analgesics

  1987cited by this paper
• Potential analgesic contribution from morphine-6-glucuronide in CSF.

  1987cited by this paper
• Morphine-6-glucuronide, a potent mu agonist.

  1987cited by this paper
• Morphine intoxication in renal failure; the role of morphine-6-glucuronide.

  1986cited by this paper
• Metabolism of narcotics.

  1984cited by this paper
• Metabolism of narcotics.

  1984cited by this paper
• Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography.

  1982cited by this paper
• Letter: Tubal pregnancy and failed sterilisation.

  1975cited by this paper

• Adult Cancer Pain, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

  2025cites this paper
• Protective effect of dexmedetomidine against delayed bone healing caused by morphine via PI3K/Akt mediated Nrf2 antioxidant defense system

  2024cites this paper
• Revision of Pharmacological Treatment Recommendations for Cancer Pain: Clinical Guidelines from the Japanese Society of Palliative Medicine

  2022cites this paper
• Pain management in head and neck cancer

  2022cites this paper
• Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline

  2022cites this paper
• Opioid Use in the Nondialysis Chronic Kidney Disease Population.

  2021cites this paper
• Understanding Cancer Pain and Controlling Pain: Focusing on Patients With Metastatic Urologic Cancer

  2021cites this paper
• Effect of wrist-ankle acupuncture therapy combined with auricular acupuncture on cancer pain: A four-parallel arm randomized controlled trial.

  2020cites this paper
• Effect of Environmental Exposure and Pharmacogenomics on Drug Metabolism.

  2020cites this paper
• Assessment and Management of Chronic Pain in the Seriously Ill.

  2019cites this paper
• Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

  2019cites this paper
• Opioid Management in Older Adults with Chronic Kidney Disease: A Review.

  2019cites this paper
• Opioids

  2019cites this paper
• Clinical Approaches to Adult Cancer Pain

  2019cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• The feasibility of physiologically based pharmacokinetic modeling in forensic medicine illustrated by the example of morphine

  2018cites this paper
• The use of opioids in cancer patients with renal impairment—a systematic review

  2017cites this paper
• Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide

  2017cites this paper
• Complications of Opioid Therapy

  2016cites this paper
• Evidence for Neurotoxicity Due to Morphine or Hydromorphone Use in Renal Impairment: A Systematic Review

  2016influential citation
• Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals

  2016cites this paper
• Opioide bei Nichttumorschmerz im höheren Lebensalter

  2015cites this paper
• Oncological Pain and Clinical Approaches

  2015cites this paper
• Serum and urine concentrations of morphine and morphine metabolites in patients with advanced cancer receiving continuous intravenous morphine: an observational study

  2015cites this paper
• Anesthetic pharmacology for kidney transplantation.

  2015cites this paper
• Polymorphisms and Haplotypes of the UDP-Glucuronosyltransferase 2B7 Gene Promoter

  2014cites this paper
• Study of Genetic Factors Involved in Pain Perception and Morphine Analgesia in Cancer-Related Pain

  2014cites this paper
• Morphine glucuronidation increases its analgesic effect in guinea pigs.

  2014cites this paper
• Anesthesia for Pancreas Transplantation

  2013cites this paper
• Mu Opioids and Their Receptors: Evolution of a Concept

  2013cites this paper
• Chapter 2 – How Should Opioids Be Started and Titrated in Hospital or Inpatient Settings?

  2013cites this paper
• In vitro morphine metabolism by rat microglia.

  2013cites this paper
• The medical treatment of cancer pain

  2013cites this paper
• Plasma morphine and metabolite concentrations are associated with clinical effects of morphine in cancer patients.

  2013cites this paper
• Pharmacological characteristics and clinical application of trans- dermal fentanyl in cancer pain management

  2013cites this paper
• Variability in UDP-glucuronosyltransferase genes and morphine metabolism: observations from a cross-sectional multicenter study in advanced cancer patients with pain

  2013cites this paper
• Overview of Supportive Care in Patients Receiving Chemotherapy

  2012cites this paper
• Integration of Palliative Care in Chronic Critical Illness Management

  2012cites this paper
• Integrating palliative care with intensive care for critically ill patients with lung cancer

  2012cites this paper
• The Metabolism of Opioid Agents and the Clinical Impact of Their Active Metabolites

  2011cites this paper
• Aliphatic and aromatic oxidations, epoxidation and S-oxidation of prodrugs that yield active drug metabolites.

  2011cites this paper
• A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: A European Palliative Care Research Collaborative opioid guidelines project

  2011cites this paper
• The distribution of opiates, cocaine and their metabolites in skeletal muscle tissue and vitreous humour as an aid to post-mortem toxicological interpretation

  2011cites this paper
• Morphine Inhibits Murine Dendritic Cell IL-23 Production by Modulating Toll-like Receptor 2 and Nod2 Signaling*

  2011cites this paper
• Higher doses of opioids in patients who need palliative sedation prior to death: cause or consequence?

  2011cites this paper
• Opioid Receptors: The Early Years

  2011cites this paper
• Strong opioids in cancer pain : clinical and pharmacogenetic factors influencing an individual's response to morphine and oxycodone

  2010cites this paper
• Adult cancer pain.

  2010cites this paper
• Adult cancer pain.

  2010cites this paper
• Chronic morphine administration delays wound healing by inhibiting immune cell recruitment to the wound site.

  2010cites this paper
• The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain

  2010cites this paper
• Morphine suppresses tumor angiogenesis through a HIF-1alpha/p38MAPK pathway.

  2010cites this paper
• Immunopathology and Infectious Diseases Chronic Morphine Administration Delays Wound Healing by Inhibiting Immune Cell Recruitment to the Wound Site

  2010cites this paper
• Short introduction and history.

  2010cites this paper
• Adult Cancer Pain: Clinical Practice Guidelines in Oncology

  2010cites this paper
• Pharmacology of opioid analgesia: Clinical principles

  2009cites this paper
• Opioid rotation: logical choices for pain that is poorly responsive to morphine

  2009cites this paper
• Morphine Disrupts Interleukin-23 (IL-23)/IL-17-Mediated Pulmonary Mucosal Host Defense against Streptococcuspneumoniae Infection

  2009cites this paper
• Palliative Care Pain Management

  2009cites this paper
• Pharmacogenetic Treatments for Drug Addiction: Alcohol and Opiates

  2008cites this paper
• Management of Expected and Unexpected Opioid-related Side Effects

  2008cites this paper
• Morphine‐6‐glucuronide (M6G) for postoperative pain relief

  2008cites this paper
• Contribution of UDP-Glucuronosyltransferase 1A1 and 1A8 to Morphine-6-Glucuronidation and Its Kinetic Properties

  2008cites this paper
• Pharmacotherapy of pain in older adults.

  2008cites this paper
• Pharmacokinetics and Pharmacodynamics of Selected Opioids

  2007cites this paper
• Adult cancer pain.

  2007cites this paper
• Of mice and men: What can we predict from the effects of morphine in a mouse model of bone cancer?

  2007cites this paper
• Ketamine as an adjuvant for treatment of cancer pain in children and adolescents.

  2007cites this paper
• Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy.

  2007cites this paper
• CHAPTER 18 – Management of Opioid-Related Side Effects

  2006cites this paper
• Pain Management in Cancer

  2006cites this paper
• HPLC determination of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human serum of oncological patients after administration of morphine drugs.

  2006cites this paper
• Symbiotic relationship of pharmacogenetics and drugs of abuse

  2006cites this paper
• Opioid metabolites.

  2005cites this paper
• Postoperative pain management: a practical review, part 1.

  2005cites this paper
• Postoperative pain management: a practical review, part 2.

  2005cites this paper
• Morphine‐6‐glucuronide: Actions and mechanisms

  2005cites this paper
• Proceedings of the Symposium "Updates of the Clinical Pharmacology of Opioids with Special Attention to Long-Acting Drugs"

  2005cites this paper
• Morphine analgesia in cancer pain: role of the glucuronides.

  2005cites this paper
• Opioids and the management of cancer pain

  2005cites this paper
• Interpretation of Opioid Levels: Comparison of Levels During Chronic Pain Therapy to Levels from Forensic Autopsies

  2005cites this paper
• Morphine metabolites as novel analgesic drugs?

  2004cites this paper
• Manejo farmacológico del dolor crónico oncológico. Una aproximación actual

  2004cites this paper
• Pain management in the intensive care unit.

  2004cites this paper
• Complications of opiate pharmacotherapy

  2004cites this paper
• Les troubles psychiques induits par les opiacés

  2004cites this paper
• Prolonged uncontrolled pain, psychological distress, and opioid escalation.

  2004cites this paper
• Multiple opiate receptors: déjà vu all over again.

  2004cites this paper
• Relationships among morphine metabolism, pain and side effects during long-term treatment: an update.

  2003cites this paper
• Anticipating and treating opioidassociated adverse effects

  2003cites this paper
• Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review.

  2003cites this paper
• Cancer Pain: Pharmacology of analgesia: basic principles

  2003cites this paper
• A pharmacogenetic study of uridine diphosphate–glucuronosyltransferase 2B7 in patients receiving morphine

  2003cites this paper
• Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients

  2003cites this paper
• Role of P‐glycoprotein in the intestinal absorption and clinical effects of morphine

  2003cites this paper
• In search of a role for the morphine metabolite morphine-3-glucuronide.

  2003cites this paper
• Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain

  2003cites this paper
• The oral-to-intravenous equianalgesic ratio of morphine based on plasma concentrations of morphine and metabolites in advanced cancer patients receiving chronic morphine treatment

  2003cites this paper
• Identification and management of delirium in the critically ill patient with cancer.

  2003cites this paper
• Morfina a funkcje poznawcze

  2003cites this paper